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Where have we been? Where Are We Going? 
Why Perform the CIRT and CANTOS Trials? 
 
From Bench to Bedside to Population and Back: 
A Story of Clinical Translation 
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What is translational research? 
How does an integrated health care system 
support it? 
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Inflammation, Atherothrombosis, and Vascular Prevention: 
Three Translational Questions 
Is there evidence that individuals with elevated levels of 
inflammatory biomarkers are at high vascular risk even 
when other risk factors are acceptable? 1995-2002   
Is there evidence that individuals identified at increased 
risk due to inflammation benefit from a therapy they 
otherwise would not have received? 2002-2008   
Is there evidence that reducing inflammation per se will 
reduce vascular events?  2009 -  
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hsCRP, Aspirin, and Risks of Future Myocardial Infarction 
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Markers of Inflammation in the Prediction 
of Cardiovascular Disease in Women 
CRP, IL-6 and the Risk for Developing 
Type-2 Diabetes in the Women’s Health Study 
Pradhan et al JAMA 2001; 286:327-34 
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The net reclassification improvement when CRP was added to traditional 
risk factors was 11.8 % for hard CHD (P= 0.009), a value greater than that 
of LDL, HDL, or blood pressure in the Framingham Data 
www.reynoldsriskscore.org 
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“The Reynolds Risk Score was better calibrated than the Framingham model in  
this large external validation cohort. The Reynolds score also showed improved  
discrimination overall in black and white women. Large differences in risk 
estimates exist between models, with clinical implications for statin therapy.” 
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Inflammation, Atherothrombosis, and Vascular Prevention: 
Three Translational Questions 
Is there evidence that individuals with elevated levels of 
inflammatory biomarkers are at high vascular risk even 
when other risk factors are acceptable? 1995-2002   
Is there evidence that individuals identified at increased 
risk due to inflammation benefit from a therapy they 
otherwise would not have received? 2002-2008   
Is there evidence that reducing inflammation per se will 
reduce vascular events?  2009 -  
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Inflammation, Statin Therapy, and hsCRP: Initial Observations 
Inflammation Present Inflammation Absent 
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Primary Prevention : Whom Should We Treat ? 
N Engl J Med. 2002;347:1157-1165. 
Pr
ob
ab
ili
ty
 o
f E
ve
nt
-fr
ee
 S
ur
vi
va
l hsCRP <  2, LDL <  130 
hsCRP >  2, LDL >  130 
hsCRP <  2, LDL >  130 
hsCRP >  2, LDL <  130 
hsCRP as a Method to Target Statin Therapy in 
Primary Prevention: AFCAPS/TexCAPS 
 
Study Group               Statin Placebo NNT 
 
low LDLC / low CRP     0.025  0.022 ---- 
 
low LDLC / high CRP     0.029  0.051   48 
 
high LDLC / low CRP     0.020  0.050   33 
 
high LDLC / high CRP        0.038  0.055   58 
   
Median LDLC = 150 mg/dL 
Median CRP = 2 mg/L 
Ridker et al N Engl J Med 2001;344:1959-65 
Rosuvastatin  20 mg (N= 8901) 
 
MI 
Stroke 
Unstable 
 Angina 
CVD Death 
CABG/PTCA 
4-week  
run-in 
No Prior CVD or DM 
Men > 50, Women > 60 
 LDL < 130 mg/dL 
 hsCRP > 2 mg/L 
JUPITER 
Trial Design 
Placebo (N= 8901) 
Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Costa Rica,  
Denmark, El Salvador, Estonia, Germany, Israel, Mexico, Netherlands,  
Norway, Panama, Poland, Romania, Russia, South Africa, Switzerland,  
United Kingdom, Uruguay, United States, Venezuela 
Mean LDLC 104 mg/dL, Mean HDLC 50 mg/dL, hsCRP 4 mg/L 
JUPITER 
Multi-National Randomized Double Blind Placebo Controlled Trial of  
Rosuvastatin in the Prevention of Cardiovascular Events 
Among Individuals With Low LDL and Elevated hsCRP 
Ridker et al NEJM 2008;359:2195-2207 
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JUPITER 
Primary Trial Endpoint : MI, Stroke, UA/Revascularization, CV Death 
Placebo 251 / 8901 
Rosuvastatin 142 / 8901 
HR 0.56, 95% CI 0.46-0.69 
P < 0.00001 
Number Needed to Treat (NNT5) = 25 
- 44 % 
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JUPITER 
Arterial Revascularization / Unstable Angina 
Placebo (N = 143) 
Rosuvastatin (N = 76) 
HR 0.53, 95%CI 0.40-0.70 
P < 0.00001 
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JUPITER 
Secondary Endpoint – All Cause Mortality 
Placebo 247 / 8901 
Rosuvastatin 198 / 8901 
HR 0.80, 95%CI 0.67-0.97 
P= 0.02 
- 20 % 
0 1 2 3 4 
0.
00
 
0.
01
 
0.
02
 
0.
03
 
0.
04
 
0.
05
 
0.
06
 
C
um
ul
at
iv
e 
In
ci
de
nc
e 
Number at Risk Follow-up (years) 
Rosuvastatin 
Placebo 
8,901 8,847 8,787 6,999 4,312 2,268 1,602 1,192 683 227 
8,901 8,852 8,775 6,987 4,319 2,295 1,614 1,196 684 246 
NEJM 2008;359:2195-2207 
JUPITER 
Primary Endpoint – Understudied or “Low Risk” Subgroups  
0.25 0.5 1.0 2.0 4.0 
Rosuvastatin Superior Rosuvastatin Inferior 
Women 
Age > 70 
Framingham Risk < 10 % 
Black, Hispanic, Other 
No Hypertension 
All Participants 
   N   HR (95%CI) 
 6,801 0.54 (0.37-0.80) 
 5,695 0.61 (0.46-0.82) 
8,882        0.56 (0.38-0.83) 
 5,117 0.63 (0.41-0.98) 
 7,586 0.62 (0.44-0.87) 
17,802 0.56 (0.46-0.69) 
BMI < 25 mg/m2  4,073 0.59 (0.40-0.87) 
No metabolic Syndrome 10,296        0.49 (0.37-0.65) 
Understudied Subgroups 
“Low Risk” Subgroups 
Ridker et al NEJM 2008;359:2195-2207 
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JUPITER 
Adverse Events and Measured Safety Parameters  
Event       Rosuvastatin Placebo      P 
   
Any SAE   1,352 (15.2)  1,337 (15.5)  0.60 
Muscle weakness  1,421 (16.0)  1,375 (15.4)  0.34 
Myopathy        10 (0.1)         9 (0.1)  0.82 
Rhabdomyolysis         1 (0.01)*        0 (0.0)  -- 
Incident Cancer     298 (3.4)     314 (3.5)  0.51 
Cancer Deaths       35 (0.4)       58 (0.7)  0.02   
Hemorrhagic stroke        6 (0.1)         9 (0.1)  0.44 
 
GFR (ml/min/1.73m2 at 12 mth)        66.8 (59.1-76.5)   66.6 (58.8-76.2) 0.02  
ALT > 3xULN       23  (0.3)       17 (0.2)  0.34 
 
Fasting glucose (24 mth)     98   (91-107)     98 (90-106) 0.12 
HbA1c (% at 24 mth)      5.9   (5.7-6.1)    5.8 (5.6-6.1) 0.01 
Glucosuria (12 mth)      36 (0.5)      32 (0.4)  0.64  
Incident Diabetes**   270  (3.0)    216 (2.4)  0.01 
 
  
 
*Occurred after trial completion, trauma induced.     All values are median (interquartile range) or N (%) 
**Physician reported 
JUPITER 
Statins and the Development of Diabetes 
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Statin Better Statin Worse 
HR    (95% CI) 
PROSPER Pravastatin 1.34   (1.06–1.68) 
LIPID Pravastatin 0.91   (0.72–1.18) 
CORONA Rosuvastatin 1.13   (0.86–1.50) 
(Hypothesis Testing Trials) 1.12   (1.04–1.30) 
(Hypothesis Generating Trial) 
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Ridker et al Lancet 2012;380: 
JUPITER 
Statin Highly Effective in All Patients – Primary Endpoint  
HR 0.51, 95% CI 0.40-0.67 
Normal Fasting Glucose 
HR 0.69, 95% CI 0.49-0.98 
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Cardiovascular Benefits and Diabetes Risks of Statin  
Therapy in Primary Prevention: The JUPITER Trial 
 
• In absolute terms for those without a major diabetes risk 
factor, 86 vascular events or death were avoided by 
statin therapy with no excess cases of diabetes 
diagnosed. 
• In absolute terms for those with a major diabetes risk 
factor, 134 vascular events or deaths were avoided by 
statin therapy for every 54 new cases of diabetes 
diagnosed.  
• Statin therapy increased the time to diagnosis of 
diabetes by 5.4 weeks. 
• Conclusion:  In primary prevention, the cardiovascular 
and mortality benefits of statin therapy exceed the 
diabetes hazard, including among individuals at high risk 
for developing diabetes. Long-term microvascular effects 
unknown.  
                  CR-46 
2010 ACC/AHA Guidelines for Assessment of 
Cardiovascular Risk in Asymptomatic Adults 
JACC November 16, 2010 
“The initial step in risk assessment in individual patients 
involves the ascertainment of a global risk score 
(Framingham, Reynolds, etc) and the elucidation of a 
family history of atherosclerotic CVD. These Class I 
recommendations which are simple and inexpensive 
determine subsequent strategies to be undertaken” 
 
Reynolds = Framingham + hsCRP + family history   
                  CR-47 
    Primary Goal : LDLC 
 
High    CAD, CVA, PVD  <2mmol/L or 50% reduction  Class I 
    Most pts with Diabetes     Level A 
    FRS > 20 % 
    RRS > 20 % 
 
Moderate   FRS 10- 19 %  <2mmol/L or 50 % reduction  Class IIA 
    RRS 10-19 %      Level A 
    LDL > 3.5 mmol/L 
    TC/HDLC > 5.0 
    hsCRP > 2 in 
        men >50 yr 
        women > 60 yr 
 
Low    FRS < 10 %  <5mmol/L   Class IIA 
        Level A 
 
Secondary Targets :  TC/HDLC < 4, non HDLC < 3.5 mol/L,  
       hsCRP < 2 mg/L, TG < 1.7 mol/L, ApoB/A<0.8  
 
2009 Canadian Cardiovascular Society (CCS) 
Guidelines for the Diagnosis and Treatment of Dyslipidemia 
and Prevention of Cardiovascular Disease in the Adult 
FRS > 20 
or DM or 
Family history 
LDLC > 160 hsCRP > 2 
No Evidence 
Of Benefit High LDL 
Low HDL High hsCRP 
Benefit 
Untested 
 
Guidelines : Statin Therapy in Primary Prevention 
What works and in whom? 
WOSCOPS  
HR 0.70 (0.57-0.84) 
MEGA 
HR O.67 (0.49-0.91) 
(pravastatin) 
 
AFCAPS/TexCAPS 
HR 0.63 (0.50-0.79) 
(lovastatin) 
 
JUPITER 
HR 0.56 (0.46-0.69) 
(rosuvastatin) 
Low LDL 
Low hsCRP 
High HDL 
Circ Cardiovasc Qual Outcomes 2012;5:592-3 
Eur Heart J 2013;34:1258-61  
JUPITER 
Consistent Effects in All Geographic Regions, All Pre-Specified Subgroups  
0.25 0.5 1.0 2.0 
Rosuvastatin Superior Rosuvastatin Inferior 
   N 
 
USA   4021 
 
Canada  2020 
 
European Union 6023 
 
Total   17802  
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Inflammation, Atherothrombosis, and Vascular Prevention: 
Three Translational Questions 
Is there evidence that individuals with elevated levels of 
inflammatory biomarkers are at high vascular risk even 
when other risk factors are acceptable? 1995-2002   
Is there evidence that individuals identified at increased 
risk due to inflammation benefit from a therapy they 
otherwise would not have received? 2002-2008   
Is there evidence that reducing inflammation per se will 
reduce vascular events?  2009 -  
51 
01
2
3
4
5
hs
C
R
P 
(m
g/
L)
 
0
20
40
60
80
100
120
140
LD
L 
 (m
g/
dL
) 
Months 
0 12 24 36 48 
JUPITER 
Achieved LDLC, Achieved hsCRP, or Both?  
LDL decrease 50 percent at 12 months  
hsCRP decrease 37 percent at 12 months 
The Real Controversy: 
 
Is the large benefit 
observed in the 
JUPITER trial due to 
lipid lowering, to 
inflammation inhibition, 
or to a combination of 
these two processes? 
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Inflammation and Thrombosis 
Venous Endothelium- transmission electron 
micrograph 
JUPITER 
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Number at Risk Follow-up (years) 
Rosuvastatin 
Placebo 
8,901 8,648 8,447 6,575 3,927 1,986 1,376 1,003 548 161 
8,901 8,652 8,417 6,574 3,943 2,012 1,381 993 556 182 
HR 0.57, 95%CI 0.37-0.86 
P= 0.007 
Placebo 60 / 8901 
Rosuvastatin 34 / 8901 
- 43 % 
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Glynn et al NEJM 2010 
                  CR-56 
JUPITER 
Absolute Risk Reduction Increases With Increasing Levels of hsCRP 
0.20 0.5 1.0 2.0 
Better Worse 
Baseline hsCRP 
>10 mg/L _ 
>9 mg/L _ 
>8 mg/L _ 
>7 mg/L _ 
>6 mg/L _ 
>5 mg/L _ 
>4 mg/L _ 
>3 mg/L _ 
>2 mg/L _ 
   N   
 2,503 
 3,071 
 3,839 
 4,723 
 5,897 
 7,425 
 9,726 
12,939 
17,802 
1.0 2.0 3.0 4.0 5.0 
Placebo Event Rate 
Ridker et al, Am J Card 2010;106:206-9 
JUPITER 
LDL reduction, hsCRP reduction, or both? 
 
 
 
   N Rate 
 
Placebo   7832 1.11 
LDL>70mg/dL,hsCRP>2 mg/L 1384 1.11 
LDL<70mg/dL,hsCRP>2 mg/L 2921 0.62 
LDL>70mg/dL,hsCRP<2 mg/L   726 0.54 
LDL<70mg/dL,hsCRP<2 mg/L 2685 0.38 
 
 
 
    
Placebo   7832 1.11 
LDL>70mg/dL,hsCRP>1 mg/L 1874 0.95 
LDL<70mg/dL,hsCRP>1 mg/L 4662 0.56 
LDL>70mg/dL,hsCRP<1 mg/L   236 0.64 
LDL<70mg/dL,hsCRP<1 mg/L   944 0.24 
 
1.0 0.5 0.25 2.0 4.0 
P < 0.001 
Rosuvastatin 
Better 
Rosuvastatin  
Worse 
P < 0.001 
Full Adjusted Hazard Ratio 
0.21, 95% CI 0.09-0.52, P < 0.0001 
Ridker et al Lancet 2009;373:1175-82 
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JUPITER 
LDL reduction, hsCRP reduction, or both? 
JUPITER GWAS:  
 
The genetic determinants of 
rosuvastatin-induced LDL-C 
reduction do not predict 
rosuvastatin-induced CRP 
reduction 
 
The genetic determinants of 
rousvastatin-induced CRP 
reduction do not predict 
rosuvastatin-induced LDL-C 
reduction  
Chasman et al, 2012 Circulation Cardiovascular Genetics 
Chu et al, 2012 Circulation Cardiovascular Genetics  
                  CR-59 Emerging Risk Factor Collaborators, Lancet January 2010 
0.5 1.0 1.2 1.4  1.8 
hsCRP 
 
Systolic BP 
 
Total cholesterol 
 
Non-HDLC 
1.37 (1.27-1.48) 
 
1.35 (1.25-1.45) 
 
1.16 (1.06-1.28) 
 
1.28 (1.16-1.40) 
Risk Ratio (95%CI) 
Meta-analysis of 54 Prospective Cohort Studies: 
The magnitude of independent risk associated with inflammation is  
at least as large, if not larger, than that of BP and cholesterol  
Risk Ratio (95%CI) per 1-SD higher usual values 
Adjusted for age, gender, smoking, diabetes, BMI, triglycerides, alcohol, lipid levels, and hsCRP 
Can Targeted Anti-Inflammatory 
Therapy Reduce Cardiovascular 
Event Rates and Prolong Life? 
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Testing the Inflammatory Hypothesis of Atherothrombosis: 
Do we attack the biomarker or attack the process? 
Stable CAD (post MI) 
On Statin, ACE/ARB, BB, ASA  
Persistent Evidence of Inflammation 
Anti-Inflammatory 
Intervention 
       Placebo       
    
Nonfatal MI, Nonfatal Stroke, Cardiovascular Death, Incident T2DM 
Ridker PM. Thromb Haemost 2009 
How to define? 
Cardiovascular Inflammation Reduction Trial (CIRT)  
What 
agent  
to study? 
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Issues in the Selection of Anti-inflammatory Agents for 
Trials of Cardiovascular Inflammation Inhibition 
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LDL 
 
 
HDL 
 
 
TG 
 
 
Chylo 
 
 
CRP / IL-6 
 
 
Statins TNF 
inhibition 
IL-6 
Inhibition 
Issues in the Selection of Anti-inflammatory Agents for 
Trials of Cardiovascular Inflammation Inhibition 
LDM IL-1β 
inhibition 
Cohort  Group HR*    (95 % CI) Endpoint  Exposure 
 
Wichita  RA 0.4   (0.2 - 0.8) Total Mortality LDM 
Choi 2002   0.3   (0.2 - 0.7) CV Mortality LDM 
   0.4   (0.3 – 0.8) CV Mortality LDM <  15 mg/wk 
 
Netherlands RA 0.3   (0.1 – 0.7) CVD  LDM only 
van Helm 2006  0.2   (0.1 – 0.5) CVD  LDM +  SSZ 
   0.2   (0.1 – 1.2) CVD  LDM +  HCQ 
   0.2   (0.1 – 0.5) CVD  LDM +  SSZ +  HCQ 
 
Miami VA  PsA 0.7   (0.6 – 0.9) CVD  LDM 
Pradanovich 2005  0.5   (0.3 – 0.8) CVD  LDM <  15 mg/wk 
  RA 0.8   (0.7 – 1.0) CVD  LDM 
   0.6   (0.5 – 0.8) CVD  LDM <  15 mg/wk 
 
CORRONA RA 0.6   (0.3 – 1.2) CVD  LDM 
Solomon 2008  0.4   (0.2 – 0.8) CVD  TNF-inhibitor  
 
QUEST-RA RA 0.85  (0.8 – 0.9) CVD  LDM 
Narango 2008  0.82  (0.7 – 0.9) MI  LDM 
   0.89  (0.8 -  1.0)  Stroke  LDM 
 
UK Norfolk RA, PsA 0.6   (0.4 – 1.0) Total Mortality LDM 
2008   0.5   (0.3 – 1.1) CV Mortality LDM  
LDM and CVD: Observational Evidence 
MTX  Control 
Bulgarelli et al, J Cardiovasc Pharmacol 2012;59:308-14 
H & E 
Anti-VSMC 
Anti-rabbit 
macrophage 
Anti-rabbit 
MMP-9 
MTX  Control 
Methotrexate Inhibits Atherogenesis in Cholesterol-fed Rabbits 
• To directly test the 
inflammatory hypothesis of 
atherothrombosis  
• To evaluate in a randomized, 
double-blind, placebo-
controlled trial whether MTX 
given at a target dose of 20 
mg po weekly over a three  
year period will reduce rates 
of recurrent myocardial 
infarction, stroke, or 
cardiovascular death among 
patients with a prior history of 
myocardial infarction and 
either type 2 diabetes or 
metabolic syndrome.  
Cardiovascular Inflammation Reduction Trial (CIRT) 
Primary Aims 
N = 7,000  NHLBI-Sponsored 
Enrollment to Start March 2013 
350 US and Canadian Sites 
Stable CAD (post MI) 
On Statin, ACE/ARB, BB, ASA  
Persistent Evidence of Inflammation 
Diabetes or Metabolic Syndrome 
MTX 15-20 mg 
Weekly  
       Placebo       
    
Nonfatal MI, Nonfatal Stroke,  
Cardiovascular Death 
Cardiovascular Inflammation Reduction Trial (CIRT) 
Forms, Updates, and More Information – theCIRT.org website 
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Issues in the Selection of Anti-inflammatory Agents for 
Trials of Cardiovascular Inflammation Inhibition 
LDM IL-1β 
inhibition 
The Balance of IL-1 and IL-1Ra : 
Key Regulatory Proteins for Innate Immunity 
IL-1Ra 
IL-1R  
Pro-Inflammatory Anti-Inflammatory 
IL-1α 
 IL-1β 
 
IL-1: Potential Roles in Atherogenesis and 
Methods of Inhibition 
IL-1 type 1 
Receptor 
Adapted from Fearon W, Fearon D. Circulation 2008;117:2577-9 
iNOS 
 
Endothelin-1 
 
Chemokines/cytokines 
 
Adhesion molecules 
 
Endothelial & Smooth  
Muscle Proliferation 
 
Macrophage Activation 
 
Endothelial Dysfunction 
 
Athero-progression 
IL-1α,β 
 
IL-1 type II 
Decoy Receptor 
Anti IL-1β antibody 
Canakinumab 
IL-1 Receptor 
Antagonist 
Endogenous 
Exogenous Anakinra 
IL-1r/IL-1r accessory protein 
IL-1 trap 
Application of IL-1β promotes arterial intimal thickening in 
porcine coronary artery 
Shimokawa et al. (1996) J Clin Invest 97:769 
Lack of IL-1β decreases severity of atherosclerosis in ApoE-
deficient mice 
Kirii et al. (2003) Arterioscler Thromb Vasc Biol 23:656 
ApoE KO ApoE KO, IL-1β KO 
Drenth JPH, et al, NEJM 2006; 355:730-732 
NLRP3 Cryopyrin Inflammasome, Caspase-1, and IL-1B Maturation 
Endogenous Danger Signals in Vascular Biology? 
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                  CR-74 
Genetic Determinants of Plasma CRP Level 
Dehgman et al, Circulation 2011;123:731-8 
Phase transition from soluble to crystalline as an endogenous “danger signal” 
Courtesy Eicke Latz   Phase transition from soluble to crystalline as a “danger signal” 
Duewell, P, et al, Nature 2010; 464:1357-1362 
Rajamaki K et al, PLoS One 2010;5:e11765 
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Cholesterol crystals activate the caspase-1-activating NLRP3 
inflammasome to generate IL-1β and initiate atherosclerosis  
Cholesterol 
Crystals; 
 
 
Modified 
LDL 
 
Pro-caspase-1 
ASC Cardinal 
NLRP3 
Cathepsin B 
Caspase-1 
Pro-IL-1β IL-1β 
IL-1β Vascular inflammation  hsCRP 
IL-1B mab or IL-1rA 
IL-1β 
IL-1β 
Phagosome 
Lysosome 
Phagolysosome 
NLRP3 
Inflammasome 
Innate immune cell 
Liver 
IL-6 
Duewell et al, Nature (2010) 464:1357-62 
Endogenous 
Danger  
Signal 
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Courtesy, George S. Abela, MD. 
P=0.01 P=0.003 
P=0.3 
Quartile of IL-6 (range, pg/dL) 
P Trend = 0.001 
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IL-6 and Risk of Future MI in Apparently Healthy Men  
IL6R Consortium and Emerging Risk Factors Collaboration, The Lancet 2012 
Canakinumab  (Ilaris, Novartis) 
• high-affinity human monoclonal anti-human 
interleukin-1β (IL-1β) antibody currently 
indicated for the treatment of IL-1β driven 
inflammatory diseases (Cryopyrin-Associated 
Period Syndrome [CAPS], Muckle-Wells 
Syndrome) 
• designed to bind to human IL-1β and 
functionally neutralize the bioactivity of this 
pro-inflammatory cytokine 
• long half-life (4-8 weeks) with CRP and IL-6 
reduction for up to 3 months 
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- 64.6 % 
Ridker PM, et al; Circulation 2012; 126:2739-2748 
Stable CAD (post MI) 
On Statin, ACE/ARB, BB, ASA  
Persistent Elevation  
of hsCRP (>  2 mg/L) 
Randomized 
Canakinumab 150 mg  
SC q 3 months 
Randomized 
Placebo  
    SC q 3 months     
    Primary Endpoint:  Nonfatal MI, Nonfatal Stroke, Cardiovascular Death     
Randomized 
Canakinumab 300 mg  
SC q 3 months 
Canakinumab Anti-inflammatory Thrombosis Outcomes Study 
 (CANTOS) (Ridker PI) 
Secondary Endpoints: Total Mortality, New Onset Diabetes, Other Vascular Events 
Exploratory Endpoints: DVT/PE; SVT; hospitalizations for CHF; PCI/CABG; biomarkers 
84 
Randomized 
Canakinumab 50 mg  
SC q 3 months 
N = 17,200 
Novartis 
(>6000 currently) 

Science 2012 
Science 2012 
jci   
 
“We await with great interest the outcome of an ongoing trial of 
the ability of canakinumab, a human monoclonal antibody that 
neutralizes IL-1β, to reduce CVD in high-risk patients with 
existing CVD. This placebo controlled study will be a key test of 
the hypothesis that inhibition of inflammation will be an 
important new strategy to reduce the burden of CVD”  
 
The Journal of  
Clinical Investigation    January 2013 
 
Science 2012 
jci   
 
“We await with great interest the outcome of an ongoing trial of the  
ability of canakinumab, a human monoclonal antibody that 
neutralizes IL-1β, to reduce CVD in high-risk patients with existing 
CVD. This placebo controlled study will be a key test of the 
hypothesis that inhibition of inflammation will be an important 
new strategy to reduce the burden of CVD”  
 
The Journal of  
Clinical Investigation    January 2013 
 
Probiotics, Inflammation, Weight Loss, and Vascular Risk 
FDA Food Pyramid HSPH Food Pyramid 

Advertisement Campaigns 
•$635 million (McDonald’s) 
•$298 million (Burger King) 
•$224 million (Coca Cola) 
Photo courtesy of Randal Thomas 
Bench Bedside Population Populat ion 
   
What is translational research? 
How does an integrated health care system 
support it? 
Affiliated 
Netw ork 
Hospitals 
Clinics 
T1, T2, T3 
Tillett and Francis  
J Exp Med 1930 
3rd serologic fraction  
“fraction C”  
isolated 
from patients 
infected with 
 pneumococcus 
“C-reactive protein” 
Maclyn McCarty 
J Exp Med 1947;85:491-8 
 
Crystallization of CRP 
 
 
Maclyn McCarty 
Oswald Avery, Colin MacLeod 
“The Transforming Principle” 
Genes are made of DNA 
Osmond A 
Shelton E*  
PNAS 1977; 
74:739-43 
 
Pentraxin 
Structure 
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Inflammation, Atherothrombosis, and Vascular Prevention: 
Three Crucial Questions 
Is there evidence that individuals with elevated levels of 
inflammatory biomarkers are at high vascular risk even 
when other risk factors are acceptable?   Yes 
Is there evidence that individuals identified at increased 
risk due to inflammation benefit from a therapy they 
otherwise would not have received?   Yes 
Is there evidence that reducing inflammation per se will 
reduce vascular events and slow progression of 
diabetes?   CIRT, CANTOS – Lets find out 
100 
For More Information :  (855) 437-9330   
theCIRT.org      theCANTOS.org 
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